Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | POLA1 | P09884 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 6/20 | 0.48 |
| ▸ | CDK1 | P06493 | 5/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385342 | 1.00 | PDPK1 (0.59) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL14977062 | 0.84 | PDPK1 (0.61) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL28274636 | 0.83 | PDPK1 (0.56) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL16145922 | 0.81 | POLA1 (0.55) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL11876697 | 0.80 | XDH (0.67) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL14938904 | 0.79 | GDA (0.54) | PDPK1GDAPOLA1XDHPI4KA | |
| SCHEMBL16146953 | 0.79 | POLA1 (0.56) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL2730455 | 0.79 | PDPK1 (0.56) | PDPK1GDAPOLA1CDK2CDK1 | |
| SCHEMBL377763 | 0.79 | CDK2 (0.48) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL28387743 | 0.78 | PDPK1 (0.54) | PDPK1GDAPOLA1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-8288354-B2 | Natural antisense and non-coding RNA transcripts as drug targets | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-10-16 | — | — | US | claimed |
| EP-1381694-A4 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS PHARMACEUTICALS INC (US) | 2006-08-16 | — | — | EP | claimed |
| US-6730485-B2 | DETECTION OF BINDING DOMAIN IN POLYPEPTIDE; OBTAIN POLYPEPTIDE, INCUBATE WITH LIGAND, EXPOSE SPECTRUM ANALYSIS, DETECT BINDING DOMAIN IN PROTEIN | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-6730484-B2 | POLYNUCLEOTIDE OR POLYPEPTIDE, AS WELL AS METHODS FOR DETERMINING WHETHER A PARTICULAR SITE IN A TARGET MOLECULE IS AT OR NEAR THE LIGAND BINDING SITE, ARE PROVIDED. LIGAND BINDING AFFINITIES CORRESPONDING TO BOTH THE TARGET MOLECULE | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| EP-1381694-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS Pharmaceuticals, Inc. (US) | 2004-01-21 | — | — | EP | claimed |
| US-6653067-B1 | Contacting with modified/unmodified test molecule and dissociating; comparing the unseparated complexes; mass spectrometry; use in drug discovery | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | claimed |
| US-20030165915-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | claimed |
| US-20030077630-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20030013113-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2002068691-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| EP-4746853-A1 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637682-B2 | Protein translational control | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2026-05-26 | — | — | US | disclosed |
| EP-0590082-A4 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE. | ISIS PHARMACEUTICALS INC (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994008003-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE | ISIS PHARMACEUTICALS, INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0590082-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE | ISIS PHARMACEUTICALS, INC. (US) | 1994-04-06 | — | — | EP | disclosed |
| WO-1992022651-A1 | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE RAS GENE | ISIS PHARMACEUTICALS, INC. (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | PDPK1 281/4885GDA 1170/4885POLA1 2876/4885 |
| US-12637682-B2 | Protein translational control | RNGTT, RNMT, METTL16 | PDPK1 3626/4885GDA 3651/4885POLA1 2390/4885 |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | DACH1, TNNT2, CDH1 | PDPK1 2204/4885GDA 3902/4885POLA1 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.